Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective April 24, 2017, Michael L. Goldberg resigned as a
director of Rennova Health, Inc. (the Company). Mr. Goldberg had
served as a director of the Company since November 2, 2015 and
previously served as a director of Medytox Solutions, Inc. from
August 6, 2015 to November 2, 2015. The consulting agreement with
Monarch Capital LLC, of which Mr. Goldberg is the Managing
Director, remains in effect.
About Rennova Health, Inc. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc. Rennova Health, Inc. (NASDAQ:RNVA) Recent Trading Information
Rennova Health, Inc. (NASDAQ:RNVA) closed its last trading session up +0.015 at 0.966 with 362,019 shares trading hands.
